SciSparc Subsidiary NeuroThera Labs Receives Conditional TSX Approval for CliniQuantum Acquisition, Amends Terms
SPRC has more than doubled off its 52-week low of $2.98 on elevated volume (37× avg).
Summary
SciSparc's subsidiary, NeuroThera Labs, received conditional TSX regulatory approval for its acquisition of CliniQuantum, a deal valued at over $9 million, and amended the purchase agreement to include a $0.05 floor price for earn-out shares and extend the closing date.
Key Events · M&A and Partnerships · SPRC
-
Conditional Regulatory Approval Received
NeuroThera Labs, SciSparc's subsidiary, received conditional regulatory approval from the TSX Venture Exchange for its acquisition of a 54% interest in CliniQuantum Ltd.
-
Significant Acquisition Value
The acquisition is valued at approximately $9.46 million, which is substantially larger than SciSparc's current market capitalization.
-
Amendment to Share Purchase Agreement
The Share Purchase Agreement was amended to include a minimum deemed price of $0.05 per common share for NeuroThera shares issued in connection with earn-out payments, a requirement from the TSX Venture Exchange.
-
Closing Date Extended
The outside date for completing the transaction has been extended from April 30, 2026, to June 1, 2026, to allow for additional time to satisfy closing conditions.
Analysis · SPRC · Life Sciences
This 6-K provides an update on SciSparc's subsidiary NeuroThera Labs' acquisition of a 54% stake in CliniQuantum. The conditional regulatory approval from the TSX Venture Exchange is a significant step towards closing this acquisition, which is valued at approximately $9.46 million, substantially exceeding SciSparc's current market capitalization. The amendment to the Share Purchase Agreement, including a $0.05 floor price for future earn-out share issuances and an extension of the closing date to June 1, 2026, provides crucial details on the deal's structure and timeline.
At the time of this filing, SPRC was trading at $9.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6M. The 52-week trading range was $2.98 to $80.10. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.